

# Andrew H Briggs

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2766940/andrew-h-briggs-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

342  
papers

21,624  
citations

72  
h-index

141  
g-index

386  
ext. papers

25,517  
ext. citations

4.6  
avg. IF

6.87  
L-index

#	Paper	IF	Citations
342	Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. <i>Value in Health</i> , <b>2013</b> , 16, 231-50	3.3	1264
341	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>BMJ, The</i> , <b>2013</b> , 346, f1049	5.9	659
340	Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. <i>Health Economics (United Kingdom)</i> , <b>2004</b> , 13, 405-15	2.4	634
339	Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. <i>Health Economics (United Kingdom)</i> , <b>1997</b> , 6, 327-40	2.4	583
338	An introduction to Markov modelling for economic evaluation. <i>Pharmacoeconomics</i> , <b>1998</b> , 13, 397-409	4.4	578
337	Handling uncertainty in cost-effectiveness models. <i>Pharmacoeconomics</i> , <b>2000</b> , 17, 479-500	4.4	544
336	Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. <i>Value in Health</i> , <b>2005</b> , 8, 521-33	3.3	481
335	Review of statistical methods for analysing healthcare resources and costs. <i>Health Economics (United Kingdom)</i> , <b>2011</b> , 20, 897-916	2.4	440
334	Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. <i>Medical Decision Making</i> , <b>2012</b> , 32, 722-32	2.5	402
333	Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. <i>Health Economics (United Kingdom)</i> , <b>1994</b> , 3, 95-104	2.4	386
332	Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. <i>Journal of Allergy and Clinical Immunology</i> , <b>2012</b> , 130, 1049-62	11.5	383
331	Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. <i>PLoS Medicine</i> , <b>2013</b> , 10, e1001380	10.6	382
330	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Value in Health</i> , <b>2013</b> , 16, e1-5	3.3	381
329	Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. <i>Health Economics (United Kingdom)</i> , <b>2002</b> , 11, 415-30	2.4	372
328	Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. <i>Value in Health</i> , <b>2015</b> , 18, 161-72	3.3	371
327	Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. <i>Value in Health</i> , <b>2012</b> , 15, 835-42	3.3	371
326	Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. <i>Value in Health</i> , <b>2012</b> , 15, 796-803	3.3	367

325	The death of cost-minimization analysis?. <i>Health Economics (United Kingdom)</i> , <b>2001</b> , 10, 179-84	2.4	316
324	Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. <i>Health Economics (United Kingdom)</i> , <b>2005</b> , 14, 339-47	2.4	313
323	Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. <i>BMJ, The</i> , <b>2013</b> , 346, e5595	5.9	310
322	Oral versus Intravenous Antibiotics for Bone and Joint Infection. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 425-436	59.2	304
321	Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. <i>Annual Review of Public Health</i> , <b>2002</b> , 23, 377-401	20.6	299
320	Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. <i>Medical Decision Making</i> , <b>2012</b> , 32, 667-77	2.5	287
319	Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. <i>Health Economics (United Kingdom)</i> , <b>1998</b> , 7, 723-40	2.4	275
318	Prognosis research strategy (PROGRESS) 4: stratified medicine research. <i>BMJ, The</i> , <b>2013</b> , 346, e5793	5.9	251
317	Missing... presumed at random: cost-analysis of incomplete data. <i>Health Economics (United Kingdom)</i> , <b>2003</b> , 12, 377-92	2.4	232
316	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Cost Effectiveness and Resource Allocation</i> , <b>2013</b> , 11, 6	2.4	230
315	Inhaler competence in asthma: common errors, barriers to use and recommended solutions. <i>Respiratory Medicine</i> , <b>2013</b> , 107, 37-46	4.6	228
314	Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. <i>Health Economics (United Kingdom)</i> , <b>2004</b> , 13, 461-75	2.4	220
313	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>International Journal of Technology Assessment in Health Care</i> , <b>2013</b> , 29, 117-22	1.8	191
312	Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). <i>Value in Health</i> , <b>2008</b> , 11, 886-97	3.3	185
311	The distribution of health care costs and their statistical analysis for economic evaluation. <i>Journal of Health Services Research and Policy</i> , <b>1998</b> , 3, 233-45	2.4	180
310	Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. <i>Statistical Methods in Medical Research</i> , <b>2002</b> , 11, 455-68	2.3	176
309	Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. <i>European Heart Journal</i> , <b>2015</b> , 36, 100-11	9.5	174
308	Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. <i>Value in Health</i> , <b>2013</b> , 16, 703-19	3.3	174

307	A Bayesian approach to stochastic cost-effectiveness analysis. <i>Health Economics (United Kingdom)</i> , <b>1999</b> , 8, 257-61	2.4	171
306	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>BMC Medicine</i> , <b>2013</b> , 11, 80	11.4	151
305	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>European Journal of Health Economics</i> , <b>2013</b> , 14, 367-72	3.6	136
304	<b>2006</b> ,		136
303	Value based pricing for NHS drugs: an opportunity not to be missed?. <i>BMJ, The</i> , <b>2008</b> , 336, 251-4	5.9	135
302	Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. <i>Medical Decision Making</i> , <b>2003</b> , 23, 341-50	2.5	124
301	MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 70, 1372-92	9.3	123
300	Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study. <i>BMJ, The</i> , <b>2011</b> , 343, d4044	5.9	123
299	Handling uncertainty in economic evaluations of healthcare interventions. <i>BMJ: British Medical Journal</i> , <b>1999</b> , 319, 635-8		123
298	Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. <i>Journal of Health Services Research and Policy</i> , <b>2007</b> , 12, 56-8	2.4	122
297	Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. <i>Value in Health</i> , <b>2005</b> , 8, 1-2	3.3	119
296	The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. <i>Value in Health</i> , <b>2016</b> , 19, 921-928	3.3	119
295	Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. <i>Medical Decision Making</i> , <b>2002</b> , 22, 290-308	2.5	117
294	Integrated care pathways for airway diseases (AIRWAYS-ICPs). <i>European Respiratory Journal</i> , <b>2014</b> , 44, 304-23	13.6	112
293	Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. <i>Pharmacoeconomics</i> , <b>2005</b> , 23, 619-37	4.4	104
292	Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomised controlled trial in primary care. <i>Lancet, The</i> , <b>2000</b> , 356, 1965-9	4.0	104
291	Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. <i>Value in Health</i> , <b>2014</b> , 17, 174-82	3.3	103
290	Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 72, 1297-1305	9.3	101

289	The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. <i>Value in Health</i> , <b>2008</b> , 11, 527-38	3.3	100
288	ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. <i>Clinical and Translational Allergy</i> , <b>2016</b> , 6, 47	5.2	95
287	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 138, 367-374.e2	11.5	95
286	Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation. <i>Statistics in Medicine</i> , <b>1999</b> , 18, 3245-62	2.3	94
285	3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 562-578	21.7	93
284	Cardiac Troponin T and Troponin I in the General Population. <i>Circulation</i> , <b>2019</b> , 139, 2754-2764	16.7	90
283	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Pharmacoeconomics</i> , <b>2013</b> , 31, 361-7	4.4	90
282	Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. <i>Lancet</i> , <b>2005</b> , 365, 1779-85	4.0	90
281	Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. <i>Health and Quality of Life Outcomes</i> , <b>2008</b> , 6, 105	3	86
280	Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. <i>Health Economics (United Kingdom)</i> , <b>2001</b> , 10, 675-80	2.4	83
279	Improving the transparency of prognosis research: the role of reporting, data sharing, registration, and protocols. <i>PLoS Medicine</i> , <b>2014</b> , 11, e1001671	11.6	81
278	Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. <i>Health Economics (United Kingdom)</i> , <b>2005</b> , 14, 471-85	2.4	81
277	Sensitivity analysis in economic evaluation: a review of published studies. <i>Health Economics (United Kingdom)</i> , <b>1995</b> , 4, 355-71	2.4	81
276	Outcome measurement in economic evaluations of public health interventions: a role for the capability approach?. <i>International Journal of Environmental Research and Public Health</i> , <b>2010</b> , 7, 2274-89 <sup>4.6</sup>	4.6	80
275	Meta-analysis of mixed treatment comparisons at multiple follow-up times. <i>Statistics in Medicine</i> , <b>2007</b> , 26, 3681-99	2.3	80
274	Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. <i>European Journal of Health Economics</i> , <b>2010</b> , 11, 427-34	3.6	79
273	Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial. <i>American Heart Journal</i> , <b>2016</b> , 172, 160-9	4.9	75
272	Parametric modelling of cost data: some simulation evidence. <i>Health Economics (United Kingdom)</i> , <b>2005</b> , 14, 421-8	2.4	75

271	Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion. <i>Health Economics (United Kingdom)</i> , <b>2006</b> , 15, 1-4	2.4	71
270	Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. <i>American Heart Journal</i> , <b>2005</b> , 149, 434-43	4.9	71
269	Quantifying stochastic uncertainty and presenting results of cost-effectiveness analyses. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2001</b> , 1, 25-36	2.2	71
268	Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. <i>BMJ, The</i> , <b>2006</b> , 333, 1145	5.9	70
267	Development of an economic model to assess the cost effectiveness of asthma management strategies. <i>Pharmacoeconomics</i> , <b>2002</b> , 20, 183-94	4.4	68
266	Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report. <i>Value in Health</i> , <b>2016</b> , 19, 704-719	3.3	67
265	Predicting EQ-5D values using the SGRQ. <i>Value in Health</i> , <b>2011</b> , 14, 354-60	3.3	64
264	Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2006</b> , 61, 531-6	9.3	64
263	Comparison between High-Sensitivity Cardiac Troponin T and Cardiac Troponin I in a Large General Population Cohort. <i>Clinical Chemistry</i> , <b>2018</b> , 64, 1607-1616	5.5	61
262	Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease. <i>Archives of Internal Medicine</i> , <b>2008</b> , 168, 71-9		61
261	Close Contact Casting vs Surgery for Initial Treatment of Unstable Ankle Fractures in Older Adults: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 316, 1455-1463	27.4	61
260	Sex differences in incidence, mortality, and survival in individuals with stroke in Scotland, 1986 to 2005. <i>Stroke</i> , <b>2009</b> , 40, 1038-43	6.7	60
259	How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2011</b> , 66, 765-774	9.3	57
258	Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling. <i>Medical Decision Making</i> , <b>2017</b> , 37, 427-439	2.5	56
257	Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme. <i>Diabetologia</i> , <b>2013</b> , 56, 1716-25	10.3	54
256	Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. <i>European Respiratory Journal</i> , <b>2010</b> , 35, 532-9	13.6	54
255	Power and sample size calculations for stochastic cost-effectiveness analysis. <i>Medical Decision Making</i> , <b>1998</b> , 18, S81-92	2.5	54
254	'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. <i>European Heart Journal</i> , <b>2018</b> , 39, 2546-2550	9.5	53



253	Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review. <i>Health Technology Assessment</i> , <b>2014</b> , 18, v-vi, 1-175	4.4	53
252	Statistical approaches to handling uncertainty in health economic evaluation. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2004</b> , 16, 551-61	2.2	52
251	The Ankle Injury Management (AIM) trial: a pragmatic, multicentre, equivalence randomised controlled trial and economic evaluation comparing close contact casting with open surgical reduction and internal fixation in the treatment of unstable ankle fractures in patients aged over 60 years. <i>Health Technology Assessment</i> , <b>2016</b> , 20, 1-158	4.4	52
250	Expanding access to HAART: a cost-effective approach for treating and preventing HIV. <i>Aids</i> , <b>2010</b> , 24, 1929-35	3.5	51
249	One-year outcomes and a cost-effectiveness analysis for smokers accessing group-based and pharmacy-led cessation services. <i>Nicotine and Tobacco Research</i> , <b>2011</b> , 13, 135-45	4.9	49
248	Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. <i>European Heart Journal</i> , <b>2006</b> , 27, 796-801	9.5	49
247	Operationalising the capability approach as an outcome measure in public health: The development of the OCAP-18. <i>Social Science and Medicine</i> , <b>2015</b> , 142, 68-81	5.1	48
246	A Bayesian approach to stochastic cost-effectiveness analysis. An illustration and application to blood pressure control in type 2 diabetes. <i>International Journal of Technology Assessment in Health Care</i> , <b>2001</b> , 17, 69-82	1.8	48
245	Specifying the target difference in the primary outcome for a randomised controlled trial: guidance for researchers. <i>Trials</i> , <b>2015</b> , 16, 12	2.8	47
244	Acute rejection and chronic nephropathy: a systematic review of the literature. <i>Transplantation</i> , <b>2009</b> , 87, 1330-9	1.8	47
243	How cost-effective is screening for abdominal aortic aneurysms?. <i>Journal of Medical Screening</i> , <b>2007</b> , 14, 46-52	1.4	46
242	Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 76, 735-750	9.3	46
241	Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 320, 1548-1559	27.4	46
240	Acknowledging patient heterogeneity in economic evaluation : a systematic literature review. <i>Pharmacoeconomics</i> , <b>2013</b> , 31, 111-23	4.4	45
239	Incorporation of uncertainty in health economic modelling studies. <i>Pharmacoeconomics</i> , <b>2005</b> , 23, 529-36	4.4	45
238	Cost-effectiveness of lifestyle modification in diabetic patients. <i>Diabetes Care</i> , <b>2009</b> , 32, 1453-8	14.6	44
237	Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. <i>Heart</i> , <b>2007</b> , 93, 1081-6	5.1	44
236	Are financial incentives cost-effective to support smoking cessation during pregnancy?. <i>Addiction</i> , <b>2016</b> , 111, 360-70	4.6	44

235	Treatment of early-stage breast cancer in the elderly: a health-outcome-based approach. <i>Medical Decision Making</i> , <b>1998</b> , 18, 213-9	2.5	39
234	Health technology assessment in the cost-disutility plane. <i>Medical Decision Making</i> , <b>2008</b> , 28, 172-81	2.5	38
233	Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial. <i>Medical Decision Making</i> , <b>2017</b> , 37, 340-352	2.5	37
232	Spoilt for choice: implications of using alternative methods of costing hospital episode statistics. <i>Health Economics (United Kingdom)</i> , <b>2012</b> , 21, 1201-16	2.4	37
231	Comparison of behavioural activation with guided self-help for treatment of depression in adults with intellectual disabilities: a randomised controlled trial. <i>Lancet Psychiatry</i> , <b>2017</b> , 4, 909-919	23.3	37
230	Long-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). <i>PLoS ONE</i> , <b>2013</b> , 8, e72642	3.7	37
229	Cost-effectiveness of pharmacy and group behavioural support smoking cessation services in Glasgow. <i>Addiction</i> , <b>2009</b> , 104, 317-25	4.6	37
228	Centre-specific or average unit costs in multi-centre studies? Some theory and simulation. <i>Health Economics (United Kingdom)</i> , <b>2000</b> , 9, 191-8	2.4	37
227	Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT <sup>®</sup> -Lung Test (ECLS): study protocol for a randomized controlled trial. <i>BMC Cancer</i> , <b>2017</b> , 17, 187	4.8	35
226	Barrett's Oesophagus Surveillance versus endoscopy at need Study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial. <i>Journal of Medical Screening</i> , <b>2015</b> , 22, 158-64	1.4	35
225	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force.. <i>Value in Health</i> , <b>2022</b> , 25, 10-31	3.3	35
224	Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations. <i>Pharmacoeconomics</i> , <b>2019</b> , 37, 1129-1138	4.4	34
223	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). <i>Clinical and Translational Allergy</i> , <b>2016</b> , 6, 29	5.2	34
222	The Ends Justify the Mean: Outcome Measures for Estimating the Value of New Cancer Therapies. <i>Health Outcomes Research in Medicine</i> , <b>2012</b> , 3, e25-e36		34
221	Estimating the impact of stroke unit care in a whole population: an epidemiological study using routine data. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2010</b> , 81, 1301-5	5.5	34
220	The use of probabilistic decision models in technology assessment : the case of total hip replacement. <i>Applied Health Economics and Health Policy</i> , <b>2004</b> , 3, 79-89	3.4	34
219	Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. <i>American Heart Journal</i> , <b>2001</b> , 142, 537-43	4.9	34
218	Oral versus intravenous antibiotic treatment for bone and joint infections (OVIVA): study protocol for a randomised controlled trial. <i>Trials</i> , <b>2015</b> , 16, 583	2.8	33



217	Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios. <i>Value in Health</i> , <b>2014</b> , 17, 525-36	3.3	32
216	International comparison of comparative effectiveness research in five jurisdictions: insights for the US. <i>Pharmacoeconomics</i> , <b>2010</b> , 28, 813-30	4.4	32
215	The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C. <i>Medical Journal of Australia</i> , <b>1994</b> , 160, 268-272	4	32
214	Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. <i>Cancer Research</i> , <b>2020</b> , 80, 5427-5434	10.1	32
213	Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models. <i>Pharmacoeconomics</i> , <b>2018</b> , 36, 1421-1426	4.4	30
212	The progressivity of health-care financing in Kenya. <i>Health Policy and Planning</i> , <b>2014</b> , 29, 912-20	3.4	30
211	Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK. <i>British Journal of Cancer</i> , <b>2010</b> , 103, 776-86	8.7	30
210	Uterine artery embolisation or hysterectomy for the treatment of symptomatic uterine fibroids: a cost-utility analysis of the HOPEFUL study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>2007</b> , 114, 1352-62	3.7	30
209	Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods. <i>Pharmacoeconomics</i> , <b>2007</b> , 25, 223-37	4.4	30
208	Prevention of mother-to-child transmission of HIV-1 infection: alternative strategies and their cost-effectiveness. <i>Aids</i> , <b>1998</b> , 12, 1381-8	3.5	30
207	The effect of deprivation and HbA1c on admission to hospital for diabetic ketoacidosis in type 1 diabetes. <i>Diabetologia</i> , <b>2012</b> , 55, 2356-60	10.3	29
206	Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. <i>Heart</i> , <b>2018</b> , 104, 1006-1013	5.1	28
205	Access with evidence development in the UK: past experience, current initiatives and future potential. <i>Pharmacoeconomics</i> , <b>2010</b> , 28, 163-70	4.4	28
204	Population ageing and healthcare expenditure projections: new evidence from a time to death approach. <i>European Journal of Health Economics</i> , <b>2014</b> , 15, 885-96	3.6	27
203	Achieved levels of HbA1c and likelihood of hospital admission in people with type 1 diabetes in the Scottish population: a study from the Scottish Diabetes Research Network Epidemiology Group. <i>Diabetes Care</i> , <b>2011</b> , 34, 1992-7	14.6	27
202	Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. <i>Value in Health</i> , <b>2006</b> , 9, 227-35	3.3	27
201	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>2013</b> , 120, 765-70	3.7	25
200	The "hazards" of extrapolating survival curves. <i>Medical Decision Making</i> , <b>2013</b> , 33, 369-80	2.5	25

199	Model averaging in the presence of structural uncertainty about treatment effects: influence on treatment decision and expected value of information. <i>Value in Health</i> , <b>2011</b> , 14, 205-18	3.3	25
198	Estimating (quality-adjusted) life-year losses associated with deaths: With application to COVID-19. <i>Health Economics (United Kingdom)</i> , <b>2021</b> , 30, 699-707	2.4	25
197	Methods for specifying the target difference in a randomised controlled trial: the Difference Elicitation in TriAls (DELTA) systematic review. <i>PLoS Medicine</i> , <b>2014</b> , 11, e1001645	11.6	24
196	Temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland. <i>BMC Medicine</i> , <b>2010</b> , 8, 23	11.4	24
195	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2297-2308	15.1	23
194	Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources. <i>International Journal of COPD</i> , <b>2017</b> , 12, 3183-3194	3	23
193	Inpatient costs for people with type 1 and type 2 diabetes in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. <i>Diabetologia</i> , <b>2011</b> , 54, 2000-8	10.3	23
192	Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up. <i>Diabetologia</i> , <b>2014</b> , 57, 2513-20	10.3	22
191	The "e" in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. <i>Annals of the American Thoracic Society</i> , <b>2014</b> , 11 Suppl 2, S105-11	4.7	22
190	A patient-centred approach to estimate total annual healthcare cost by body mass index in the UK Counterweight programme. <i>International Journal of Obesity</i> , <b>2013</b> , 37, 1135-9	5.5	22
189	The credibility of health economic models for health policy decision-making: the case of population screening for abdominal aortic aneurysm. <i>Journal of Health Services Research and Policy</i> , <b>2007</b> , 12, 11-7	2.4	22
188	Cost-effectiveness and cost-utility of long-term management strategies for heartburn. <i>Value in Health</i> , <b>2002</b> , 5, 312-28	3.3	22
187	Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging. <i>European Respiratory Journal</i> , <b>2021</b> , 57,	13.6	22
186	Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. <i>European Journal of Health Economics</i> , <b>2014</b> , 15, 69-82	3.6	21
185	Trying to do better than average: a commentary on 'statistical inference for cost-effectiveness ratios'. <i>Health Economics (United Kingdom)</i> , <b>1997</b> , 6, 491-5	2.4	21
184	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 76, 168-190	9.3	21
183	A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for depression after psychosis: Pilot trial outcomes (ADAPT). <i>Schizophrenia Research</i> , <b>2017</b> , 183, 143-150	3.6	20
182	Count the cost of disability caused by COVID-19. <i>Nature</i> , <b>2021</b> , 593, 502-505	50.4	20

181	Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model. <i>Medical Decision Making</i> , <b>2017</b> , 37, 469-480	2.5	19
180	Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. <i>Trials</i> , <b>2015</b> , 16, 267	2.8	19
179	Age- and sex-specific trends in fatal incidence and hospitalized incidence of stroke in Scotland, 1986 to 2005. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2009</b> , 2, 475-83	5.8	19
178	Long-term weight loss following a randomised controlled trial of a weight management programme for men delivered through professional football clubs: the Football Fans in Training follow-up study. <i>Public Health Research</i> , <b>2018</b> , 6, 1-114	1.7	19
177	A cardiovascular disease policy model that predicts life expectancy taking into account socioeconomic deprivation. <i>Heart</i> , <b>2015</b> , 101, 201-8	5.1	18
176	Long-term weight loss trajectories following participation in a randomised controlled trial of a weight management programme for men delivered through professional football clubs: a longitudinal cohort study and economic evaluation. <i>International Journal of Behavioral Nutrition and Physical Activity</i> , <b>2018</b> , 15, 60	8.4	18
175	The costs and benefits of primary total hip replacement. How likely are new prostheses to be cost-effective?. <i>International Journal of Technology Assessment in Health Care</i> , <b>1998</b> , 14, 743-61	1.8	18
174	A model for analyzing the cost of main clinical events after cardiac transplantation. <i>Transplantation</i> , <b>1996</b> , 62, 615-21	1.8	18
173	Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study. <i>Medical Decision Making</i> , <b>2017</b> , 37, 453-468	2.5	17
172	Analyzing Health-Related Quality of Life in the EVOLVE Trial: The Joint Impact of Treatment and Clinical Events. <i>Medical Decision Making</i> , <b>2016</b> , 36, 965-72	2.5	17
171	Mobile phone use for contacting emergency services in life-threatening circumstances. <i>Journal of Emergency Medicine</i> , <b>2012</b> , 42, 291-298.e3	1.5	17
170	The cessation in pregnancy incentives trial (CPIT): study protocol for a randomized controlled trial. <i>Trials</i> , <b>2012</b> , 13, 113	2.8	17
169	Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection. <i>Journal of Clinical Gastroenterology</i> , <b>2004</b> , 38, S179-86	3	17
168	External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting. <i>Value in Health</i> , <b>2017</b> , 20, 397-403	3.3	16
167	Communicating the parameter uncertainty in the IQWiG efficiency frontier to decision-makers. <i>Health Economics (United Kingdom)</i> , <b>2015</b> , 24, 481-90	2.4	16
166	Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization. <i>Respiratory Medicine</i> , <b>2005</b> , 99, 1534-45	4.6	16
165	Pharmacoeconomics and pharmacoepidemiology: curious bedfellows or a match made in heaven?. <i>Pharmacoeconomics</i> , <b>2006</b> , 24, 1079-86	4.4	16
164	Transcatheter aortic valve implantation for severe aortic stenosis: the cost-effectiveness case for inoperable patients in the United Kingdom. <i>International Journal of Technology Assessment in Health Care</i> , <b>2013</b> , 29, 12-9	1.8	15

163	Power and sample size for cost-effectiveness analysis: fFN neonatal screening. <i>Contemporary Clinical Trials</i> , <b>2011</b> , 32, 893-901	2.3	15
162	Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986-2005: a retrospective cohort study. <i>BMC Neurology</i> , <b>2011</b> , 11, 38	3.1	15
161	A systematic review of continuous performance task research in children prenatally exposed to alcohol. <i>Alcohol and Alcoholism</i> , <b>2010</b> , 45, 30-8	3.5	15
160	An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 66-74	12.3	15
159	Within-trial cost and 1-year cost-effectiveness of the DiRECT/Counterweight-Plus weight-management programme to achieve remission of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , <b>2019</b> , 7, 169-172	18.1	15
158	Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. <i>Diabetes Research and Clinical Practice</i> , <b>2017</b> , 130, 21-28	7.4	14
157	Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial. <i>American Heart Journal</i> , <b>2018</b> , 201, 86-94	4.9	14
156	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Clinical Therapeutics</i> , <b>2013</b> , 35, 356-63	3.5	14
155	PATHway I: design and rationale for the investigation of the feasibility, clinical effectiveness and cost-effectiveness of a technology-enabled cardiac rehabilitation platform. <i>BMJ Open</i> , <b>2017</b> , 7, e016781 <sup>3</sup>		14
154	Development of a Conceptual Model of Disease Progression for Use in Economic Modeling of Chronic Obstructive Pulmonary Disease. <i>Medical Decision Making</i> , <b>2017</b> , 37, 440-452	2.5	14
153	Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial. <i>Value in Health</i> , <b>2015</b> , 18, 1079-87	3.7	14
152	How effective is the Forestry Commission Scotland's woodland improvement programme--'Woods In and Around Towns' (WIAT)--at improving psychological well-being in deprived urban communities? A quasi-experimental study. <i>BMJ Open</i> , <b>2013</b> , 3, e003648	3	14
151	Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes. <i>Quality of Life Research</i> , <b>2010</b> , 19, 323-31 <sup>7</sup>	3.7	14
150	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Value in Health</i> , <b>2022</b> , 25, 3-9	3.3	14
149	Pharmacoeconomics in COPD: lessons for the future. <i>International Journal of COPD</i> , <b>2008</b> , 3, 71-88	3	14
148	Transportability of comparative effectiveness and cost-effectiveness between countries. <i>Value in Health</i> , <b>2010</b> , 13 Suppl 1, S22-5	3.3	13
147	Early Signs Monitoring to Prevent Relapse in Psychosis and Promote Well-Being, Engagement, and Recovery: Protocol for a Feasibility Cluster Randomized Controlled Trial Harnessing Mobile Phone Technology Blended With Peer Support. <i>JMIR Research Protocols</i> , <b>2020</b> , 9, e15058	2	13
146	3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. <i>Health Technology Assessment</i> , <b>2019</b> , 23, 1-88	4.4	13

145	Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2020</b> , 18, 1096-1104	7.3	13
144	Cost-Effectiveness Uncertainty Analysis Methods: A Comparison of One-Way Sensitivity, Analysis of Covariance, and Expected Value of Partial Perfect Information. <i>Medical Decision Making</i> , <b>2015</b> , 35, 596-607	2.7	12
143	How methodological frameworks are being developed: evidence from a scoping review. <i>BMC Medical Research Methodology</i> , <b>2020</b> , 20, 173	4.7	12
142	Projecting long-term graft and patient survival after transplantation. <i>Value in Health</i> , <b>2014</b> , 17, 254-60	3.3	12
141	Are value of information methods ready for prime time? An application to alternative treatment strategies for NSTEMI patients. <i>International Journal of Technology Assessment in Health Care</i> , <b>2013</b> , 29, 435-42	1.8	12
140	How Do Diabetes Models Measure Up? A Review of Diabetes Economic Models and ADA Guidelines. <i>Journal of Health Economics and Outcomes Research</i> , <b>2015</b> , 3, 132-152	1.6	12
139	BEAT-IT: Comparing a behavioural activation treatment for depression in adults with intellectual disabilities with an attention control: study protocol for a randomised controlled trial. <i>Trials</i> , <b>2015</b> , 16, 595	2.8	11
138	Ankle Injury Management (AIM): design of a pragmatic multi-centre equivalence randomised controlled trial comparing Close Contact Casting (CCC) to Open surgical Reduction and Internal Fixation (ORIF) in the treatment of unstable ankle fractures in patients over 60 years. <i>BMC Musculoskeletal Disorders</i> , <b>2014</b> , 15, 78	2.8	11
137	Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. <i>Value in Health</i> , <b>2011</b> , 14, 15-23	3.3	11
136	Health impacts of environmental and social interventions designed to increase deprived communities' access to urban woodlands: a mixed-methods study. <i>Public Health Research</i> , <b>2019</b> , 7, 1-172	1.7	11
135	Type 2 diabetes remission: 2-year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)/Counterweight-Plus weight management programme. <i>Diabetologia</i> , <b>2020</b> , 63, 2112-2122	10.3	11
134	Bayesian Solutions for Handling Uncertainty in Survival Extrapolation. <i>Medical Decision Making</i> , <b>2017</b> , 37, 367-376	2.5	10
133	Fractional flow reserve versus angiography in guiding management to optimize outcomes in non-ST-elevation myocardial infarction (FAMOUS-NSTEMI): rationale and design of a randomized controlled clinical trial. <i>American Heart Journal</i> , <b>2013</b> , 166, 662-668.e3	4.9	10
132	Time trends in 30 day case-fatality following hospitalisation for asthma in adults in Scotland: a retrospective cohort study from 1981 to 2009. <i>Respiratory Medicine</i> , <b>2013</b> , 107, 1172-7	4.6	10
131	Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods. <i>Cost Effectiveness and Resource Allocation</i> , <b>2015</b> , 13, 19	2.4	10
130	Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 1754-1759	8.7	9
129	A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet. <i>Pharmacoeconomics</i> , <b>2018</b> , 36, 603-612	4.4	9
128	Hospital expenditure at the end-of-life: what are the impacts of health status and health risks?. <i>PLoS ONE</i> , <b>2015</b> , 10, e0119035	3.7	9



127	Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting?. <i>Trials</i> , <b>2011</b> , 12,	2.8	9
126	Using an iterative approach to economic evaluation in the drug development process. <i>Drug Development Research</i> , <b>2010</b> , 71, 470-477	5.1	9
125	The Design and Analysis of Stochastic Cost-Effectiveness Studies for the Evaluation of Health Care Interventions. <i>Drug Information Journal</i> , <b>2001</b> , 35, 1455-1468		9
124	Economic evaluation of integrated new technologies for health and social care: Suggestions for policy makers, users and evaluators. <i>Social Science and Medicine</i> , <b>2016</b> , 169, 141-148	5.1	9
123	SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 1332-1338	8.7	9
122	Enhancing Health Through Access to Nature: How Effective are Interventions in Woodlands in Deprived Urban Communities? A Quasi-experimental Study in Scotland, UK. <i>Sustainability</i> , <b>2019</b> , 11, 3317 <sup>2.6</sup>		8
121	Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer. <i>BMJ Open</i> , <b>2015</b> , 5, e007925	3	8
120	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMJ, The</i> , <b>2022</b> , 376, e067975	5.9	8
119	Handling Uncertainty in Economic Evaluation <sup>314-337</sup>		8
118	Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?. <i>Value in Health</i> , <b>2016</b> , 19, 800-810 <sup>3.3</sup>		8
117	Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy. <i>Value in Health</i> , <b>2016</b> , 19, 374-82	3.3	8
116	Type 2 diabetes remission: economic evaluation of the DiRECT/Counterweight-Plus weight management programme within a primary care randomized controlled trial. <i>Diabetic Medicine</i> , <b>2019</b> , 36, 1003-1012	3.5	7
115	Development and validation of a cost-utility model for Type 2 diabetes mellitus. <i>Diabetic Medicine</i> , <b>2015</b> , 32, 1023-35	3.5	7
114	Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis. <i>Cancers</i> , <b>2020</b> , 12,	6.6	7
113	The feasibility of a randomised controlled trial to compare the cost-effectiveness of palliative cardiology or usual care in people with advanced heart failure: Two exploratory prospective cohorts. <i>Palliative Medicine</i> , <b>2018</b> , 32, 1133-1141	5.5	7
112	A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia. <i>Advances in Therapy</i> , <b>2016</b> , 33, 1814-1830 <sup>4.1</sup>		7
111	Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABG-ACS). <i>Open Heart</i> , <b>2016</b> , 3, e000371	3	7
110	Use of methods for specifying the target difference in randomised controlled trial sample size calculations: Two surveys of trialists' practice. <i>Clinical Trials</i> , <b>2014</b> , 11, 300-308	2.2	7



109	Commentary: Markov models of medical prognosis. <i>BMJ: British Medical Journal</i> , <b>1997</b> , 314, 354-5		7
108	Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer. <i>ClinicoEconomics and Outcomes Research</i> , <b>2016</b> , 8, 323-33	1.7	7
107	Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia. <i>ClinicoEconomics and Outcomes Research</i> , <b>2018</b> , 10, 705-713	1.7	7
106	Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia. <i>ClinicoEconomics and Outcomes Research</i> , <b>2018</b> , 10, 715-721	1.7	7
105	Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration. <i>Pharmacoeconomics</i> , <b>2015</b> , 33, 535-6	4.4	6
104	Temporal trends and risk factors for readmission for infections, gastrointestinal and immobility complications after an incident hospitalisation for stroke in Scotland between 1997 and 2005. <i>BMC Neurology</i> , <b>2015</b> , 15, 3	3.1	6
103	Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data. <i>Medical Decision Making</i> , <b>2020</b> , 40, 460-473	2.5	6
102	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMC Medicine</i> , <b>2022</b> , 20, 23	11.4	6
101	The Scottish Alcoholic Liver disease Evaluation: A Population-Level Matched Cohort Study of Hospital-Based Costs, 1991-2011. <i>PLoS ONE</i> , <b>2016</b> , 11, e0162980	3.7	6
100	Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma. <i>BioDrugs</i> , <b>2016</b> , 30, 307-19	7.9	6
99	Artificial neural network metamodel for sensitivity analysis in a total hip replacement health economic model. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2020</b> , 20, 629-640	2.2	6
98	Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons. <i>ClinicoEconomics and Outcomes Research</i> , <b>2019</b> , 11, 551-565	1.7	5
97	Sentinel Lymph Node Biopsy for T1b Melanoma: Balancing Prognostic Value and Cost. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 5248-5256	3.1	5
96	Comparison of health state utility estimates from instrument-based and vignette-based methods: a case study in kidney disease. <i>BMC Research Notes</i> , <b>2019</b> , 12, 385	2.3	5
95	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. <i>Journal of Medical Economics</i> , <b>2017</b> , 20, 8-18	2.4	5
94	Comparative effectiveness research through the looking glass. <i>Medical Decision Making</i> , <b>2009</b> , 29, NP6-82.5		5
93	Perioperative and long-term outcomes following aortic valve replacement: a population cohort study of 4124 consecutive patients. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2011</b> , 40, 1508-14	3	5
92	Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>International Journal of Technology Assessment in Health Care</i> , <b>2022</b> , 38, e13	1.8	5

91	Toxicity and quality of life data from SCOT: An international phase III randomized (1:1) noninferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3514-3514	2.2	5
90	The impact of patient education on consideration of enrollment in clinical trials. <i>Journal of Community and Supportive Oncology</i> , <b>2018</b> , 16, e81-e88		5
89	Behavioural activation versus guided self-help for depression in adults with learning disabilities: the BeatIt RCT. <i>Health Technology Assessment</i> , <b>2018</b> , 22, 1-130	4.4	5
88	Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT. <i>Health Technology Assessment</i> , <b>2019</b> , 23, 1-146	4.4	5
87	Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane <b>1998</b> , 7, 723		5
86	SurgiCal Obesity Treatment Study (SCOTS): protocol for a national prospective cohort study of patients undergoing bariatric surgery in Scotland. <i>BMJ Open</i> , <b>2015</b> , 5, e008106	3	4
85	Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure. <i>American Heart Journal</i> , <b>2015</b> , 170, 951-60	4.9	4
84	Prices For Common Cardiovascular Drugs In The US Are Not Consistently Aligned With Value. <i>Health Affairs</i> , <b>2018</b> , 37, 1298-1305	7	4
83	A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results. <i>Medical Decision Making</i> , <b>2003</b> , 23, 252-64	2.5	4
82	A glossary of economic terms. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2004</b> , 16, 563-5	2.2	4
81	Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. <i>Wellcome Open Research</i> , <b>4</b> , 108	4.8	4
80	Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. <i>Wellcome Open Research</i> , <b>2019</b> , 4, 108	4.8	4
79	Modifying Alcohol Consumption to Reduce Obesity (MACRO): development and feasibility trial of a complex community-based intervention for men. <i>Health Technology Assessment</i> , <b>2017</b> , 21, 1-150	4.4	4
78	Cost-Benefit Implication of Gene Expression Profiling and Adjuvant Therapy in Stage IIIA Melanoma. <i>Journal of the American College of Surgeons</i> , <b>2020</b> , 231, 547-554.e1	4.4	4
77	A cardiovascular disease policy model: part 2-preparing for economic evaluation and to assess health inequalities. <i>Open Heart</i> , <b>2016</b> , 3, e000140	3	4
76	Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study. <i>International Journal of COPD</i> , <b>2019</b> , 14, 939-951	3	3
75	Using Nominal Group Technique to Identify Key Attributes of Oncology Treatments for a Discrete Choice Experiment. <i>MDM Policy and Practice</i> , <b>2019</b> , 4, 2381468319837925	1.5	3
74	A different animal? Identifying the features of health technology assessment for developers of medical technologies. <i>International Journal of Technology Assessment in Health Care</i> , <b>2020</b> , 1-7	1.8	3

73	Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective. <i>Cost Effectiveness and Resource Allocation</i> , <b>2018</b> , 16, 17	2.4	3
72	Evaluation of health in pregnancy grants in Scotland: a protocol for a natural experiment. <i>BMJ Open</i> , <b>2014</b> , 4, e006547	3	3
71	Nurse led versus lay educators support for those with asthma in primary care: a costing study. <i>BMC Pulmonary Medicine</i> , <b>2012</b> , 12, 52	3.5	3
70	Appropriate cohorts for cost-effectiveness analysis: to mix or not to mix?. <i>Medical Decision Making</i> , <b>2010</b> , 30, 424-5	2.5	3
69	Interferon-alpha in hepatitis C. Dosage, costs and benefits. <i>Pharmacoeconomics</i> , <b>1996</b> , 10, 205-9	4.4	3
68	Comparison of Lost Productivity Due to Eculizumab and Ravulizumab Treatments for Paroxysmal Nocturnal Hemoglobinuria in France, Germany, Italy, Russia, Spain, the United Kingdom, and the United States. <i>Blood</i> , <b>2019</b> , 134, 4803-4803	2.2	3
67	Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review. <i>Health and Quality of Life Outcomes</i> , <b>2020</b> , 18, 310	3	3
66	Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin. <i>Pharmacoeconomics</i> , <b>2021</b> , 39, 317-330	4.4	3
65	The impact of moderate and severe asthma exacerbations on quality of life: a post hoc analysis of randomised controlled trial data. <i>Journal of Patient-Reported Outcomes</i> , <b>2021</b> , 5, 6	2.6	3
64	Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective. <i>Respiratory Medicine</i> , <b>2018</b> , 145, 130-137	4.6	3
63	542P Growth modulation index (GMI) of larotrectinib versus prior systemic treatments for TRK fusion cancer patients. <i>Annals of Oncology</i> , <b>2020</b> , 31, S473-S474	10.3	2
62	A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for Depression After Psychosis: A Pilot Trial Protocol (ADAPT). <i>Psychosis</i> , <b>2016</b> , 8, 143-155	1.2	2
61	Cost-effectiveness analysis of a single-inhaler triple therapy for patients with advanced chronic obstructive pulmonary disease (COPD) using the FULFIL trial: A UK perspective. <i>Respiratory Medicine: X</i> , <b>2019</b> , 1, 100008	1.6	2
60	Methodology of a Novel Risk Stratification Algorithm for Patients with Multiple Myeloma in the Relapsed Setting. <i>Oncology and Therapy</i> , <b>2019</b> , 7, 141-157	2.7	2
59	ISPOR-SMDM task force's recommendations for good modeling practices-reply to letter to the editor by Corro Ramos. <i>Value in Health</i> , <b>2013</b> , 16, 1108	3.3	2
58	Searching for a threshold [Not so] <i>Journal of Health Services Research and Policy</i> , <b>2007</b> , 12, 190-191	2.4	2
57	PIN15 IMPACT ON QUALITY OF LIFE OF HEALTH STATES INDUCED BY CHRONIC HEPATITIS B INFECTION: ESTIMATES FROM UNINFECTED AND INFECTED PERSONS IN THE UK. <i>Value in Health</i> , <b>2005</b> , 8, A60	3.3	2
56	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMC Public Health</i> , <b>2022</b> , 22, 179	4.1	2

55	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMC Health Services Research</i> , <b>2022</b> , 22, 114	2.9	2
54	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. <i>Health Policy OPEN</i> , <b>2022</b> , 3, 100063	1.9	2
53	SCOT: Short Course Oncology Therapy A comparison of 12 and 24 weeks of adjuvant chemotherapy in colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, e14145-e14145	2.2	2
52	Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective. <i>Pharmacoeconomics</i> , <b>2021</b> , 39, 1343-1354	4.4	2
51	Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review. <i>BMJ Open</i> , <b>2020</b> , 10, e034209	3	2
50	A criterion-based approach to systematic and transparent comparative effectiveness: a case study in psoriatic arthritis. <i>Journal of Comparative Effectiveness Research</i> , <b>2019</b> , 8, 1265-1298	2.1	2
49	A quality-of-life mapping function developed from a grass pollen sublingual immunotherapy trial to a tree pollen sublingual immunotherapy trial. <i>Journal of Medical Economics</i> , <b>2020</b> , 23, 64-69	2.4	2
48	The EMPOWER blended digital intervention for relapse prevention in schizophrenia: a feasibility cluster randomised controlled trial in Scotland and Australia.. <i>Lancet Psychiatry</i> , <b>2022</b> , 9, 477-486	23.3	2
47	A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists. <i>Journal of Comparative Effectiveness Research</i> , <b>2018</b> , 7, 775-784	2.1	1
46	Protocol for an economic evaluation of the randomised controlled trial of culprit lesion only PCI versus immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: CULPRIT-SHOCK trial. <i>BMJ Open</i> , <b>2017</b> , 7, e014849	3	1
45	Risk stratification for diabetic eye screening. Reply to Stratton I. M. and Aldington S. J. [letter]. <i>Diabetologia</i> , <b>2014</b> , 57, 260-1	10.3	1
44	Reply to Evidence is still required for treatment as prevention for riskier routes of HIV transmission <i>Aids</i> , <b>2010</b> , 24, 2892-2893	3.5	1
43	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Applied Health Economics and Health Policy</i> , <b>2022</b> , 20, 213	3.4	1
42	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>European Journal of Health Economics</i> , <b>2022</b> , 1	3.6	1
41	A decision-analytic model of idelalisib and rituximab combination therapy versus rituximab monotherapy in relapsed, unfit chronic lymphocytic leukemia.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 7101-7101	2.2	1
40	A decision-analytic model of idelalisib in relapsed or refractory patients with indolent non-Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e17655-e17655	2.2	1
39	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant: A cost-effectiveness analysis updated with 5-year follow-up data from the pivotal trial.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 19-19	2.2	1
38	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Journal of Medical Economics</i> , <b>2022</b> , 25, 1-7	2.4	1

37	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Pharmacoeconomics</i> , <b>2022</b> , 1	4.4	1
36	Evaluation of Health in Pregnancy grants in Scotland: a natural experiment using routine data. <i>Public Health Research</i> , <b>2017</b> , 5, 1-278	1.7	1
35	Cost effectiveness of interferon in chronic active hepatitis C. <i>Medical Journal of Australia</i> , <b>1994</b> , 161, 170-170	4	1
34	Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. <i>Wellcome Open Research</i> , <b>4</b> , 108	4.8	1
33	Assessing the impact of restricted follow-up and small sample sizes on survival estimations in prostate cancer using registry data.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 294-294	2.2	1
32	Cost-effectiveness of brentuximab vedotin in relapsed or refractory systemic anaplastic large cell lymphoma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 18-18	2.2	1
31	Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic. <i>Pharmacoeconomics</i> , <b>2021</b> , 39, 1201-1208	4.4	1
30	Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis. <i>Clinical Colorectal Cancer</i> , <b>2021</b> , 20, 236-244	2.8	1
29	Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS).. <i>Trials</i> , <b>2022</b> , 23, 307	2.8	1
28	Application of a Mapping Function to Estimate Utilities for Ragweed Allergy Immunotherapy Trials. <i>Pharmacoeconomics - Open</i> , <b>2020</b> , 4, 649-655	2.1	0
27	Unfinished symphony: a tribute to the life and career of Bernie O'Brien (1959-2004). <i>Medical Decision Making</i> , <b>2004</b> , 24, 538-44	2.5	0
26	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2022</b> , 28, 146-155	1.9	0
25	Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence Models. <i>Pharmacoeconomics</i> , <b>2021</b> , 1	4.4	0
24	Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With Cancer.. <i>Value in Health</i> , <b>2022</b> , 25, 230-237	3.3	0
23	From Spreadsheets to Script: Experiences From Converting a Scottish Cardiovascular Disease Policy Model into R. <i>Applied Health Economics and Health Policy</i> , <b>2021</b> , 1	3.4	0
22	Economic evaluation of culprit lesion only PCI vs. immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: the CULPRIT-SHOCK trial. <i>European Journal of Health Economics</i> , <b>2020</b> , 21, 1197-1209	3.6	0
21	Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies. <i>Applied Health Economics and Health Policy</i> , <b>2021</b> , 19, 625-634	3.4	0
20	Intra-patient comparison from larotrectinib clinical trials in TRK fusion cancer: An expanded dataset.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3114-3114	2.2	0



19	Mendelian randomization: estimation of inpatient hospital costs attributable to obesity. <i>Health Economics Review</i> , <b>2021</b> , 11, 16	2	0
18	Stratified medicine using invasive coronary function testing in angina: A cost-effectiveness analysis of the British Heart Foundation CorMicA trial. <i>International Journal of Cardiology</i> , <b>2021</b> , 337, 44-51	3.2	0
17	Protocol for an observational cohort study investigating personalised medicine for intensification of treatment in people with type 2 diabetes mellitus: the PERMIT study. <i>BMJ Open</i> , <b>2021</b> , 11, e046912	3	0
16	Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting.. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2022</b> , 1-11	1.9	0
15	Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT. <i>Health Technology Assessment</i> , <b>2022</b> , 26, 1-174	4.4	0
14	Rational allocation of resources available for healthcare: understanding cost effectiveness analyst. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19492	5.4	
13	Statistical Issues with Trial Data and Economic Modeling for Cost-Effectiveness Evaluation <b>2012</b> , 149-166		
12	TRANSCATHETER AORTIC VALVE IMPLANTATION FOR SEVERE AORTIC STENOSIS: THE COST-EFFECTIVENESS CASE FOR INOPERABLE PATIENTS IN THE UNITED KINGDOM □ CORRIGENDUM. <i>International Journal of Technology Assessment in Health Care</i> , <b>2013</b> , 29, 112-112	1.8	
11	Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration. <i>Journal of Ophthalmology</i> , <b>2009</b> , 2009, 540431	2	
10	Health Economics in Asthma and COPD <b>2009</b> , 751-760		
9	Assessing the economic merits of managing cytomegalovirus infection in organ and stem cell transplantation. <i>Journal of Medical Economics</i> , <b>2009</b> , 12, 68-76	2.4	
8	Interferon- $\gamma$ Hepatitis C: The Authors Reply. <i>Pharmacoeconomics</i> , <b>1997</b> , 11, 491-492	4.4	
7	Empirical treatment or prompt endoscopy. <i>Lancet, The</i> , <b>2001</b> , 357, 1366	4.0	
6	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2022</b> , 1-10	1.9	
5	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>MDM Policy and Practice</i> , <b>2022</b> , 7, 23814683211061097	1.5	
4	Growth modulation index (GMI) as a comparative efficacy measure of larotrectinib versus prior systemic treatments for TRK fusion cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e15638-e15638	2.2	
3	Reporting Guidelines for Health Economic Evaluations: BMJ Guidelines for Authors and Peer Reviewers of Economic Submissions 296-305		
2	The thorny issue of value alignment: how development-focused health technology assessment can help find win-win situations for patients and healthcare systems and commercial investors. <i>International Journal of Technology Assessment in Health Care</i> , <b>2021</b> , 37, e57	1.8	



- 1 Modeling Chronic Kidney Disease in Type2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation Cohorts.. *Diabetes Therapy*, **2022**, 13, 651 3.6